Skip to main content
< Back
About
About the conference
App
Organisers & Partners
Latest updates
Press room
Registration
Venue 22
About the venue
Rooms
Call for abstracts
Programme 22
Tracks 22
Speakers 22
Side events 22
Subscribe
days
hours
minutes
seconds
E-health
Sessions
Wednesday, 23 November
10:50
Advances in toxicology
10:50
to
12:20
Central square 2 (C2)
Oral presentation session
Drug treatment
10:50
to
12:20
Knowledge market 3 (K3)
Oral presentation session
13:20
e-/m-health interventions for substance use disorders
13:20
to
14:50
Central square 3 (C3)
Oral presentation session
Global digital addiction interventions: adaptations to target audiences and effectiveness
13:20
to
14:50
Insights zone 2 (I2)
Structured session
Migration, substance use and interventions in Europe
13:20
to
14:50
Insights zone 4 (I4)
Structured session
The future for Digital Addictions Services. An update from the DigitAS-DADE Project
13:20
to
14:50
Central square 2 (C2)
Structured session
Thursday, 24 November
10:50
Online and social identities
10:50
to
12:20
Insights zone 2 (I2)
Oral presentation session
13:20
Novel approaches of alcohol use disorder
13:20
to
14:50
Central square 1 (C1)
Oral presentation session
15:00
Substance use and mental health during COVID-19
15:00
to
16:30
Knowledge market 2 (K2)
Oral presentation session
16:50
Alcohol & implementation
16:50
to
18:20
Networking zone 4 (N4)
Short communication session
Reducing harm - obstacles and opportunities
16:50
to
18:20
Networking zone 1 (N1)
e-poster guided tour
Friday, 25 November
10:50
A Digital Future? Engaging online communities of people who use drugs to influence policy and practice
10:50
to
12:20
Central square 4 (C4)
Workshop
13:20
New advances in alcohol clinical research: evidence from three large National Institute for Health Research-funded randomised controlled trials
13:20
to
14:50
Networking zone 3 (N3)
Structured session
Presentations
Wednesday, 23 November
10:50
Oral presentation
A qualitative exploration of patient’s experience of mobile telephone-delivered Contingency Management (mCM) to promote adherence to supervised methadone in UK pharmacies
10:50
to
12:20
Knowledge market 3 (K3)
Carol-Ann Getty
Oral presentation
I don’t chase drugs anymore and I’m not dead': The Impact of Safer Opioid Supply Programs in Ontario Canada on Client’s Health and Drug Use
10:50
to
12:20
Knowledge market 3 (K3)
Rose Schmidt
Oral presentation
Delivering telemedicine to vulnerable people with opioid use disorder: Outcomes of a program co-constructed and implemented with a community-based harm reduction service in Montreal, Canada
10:50
to
12:20
Knowledge market 3 (K3)
Stine Hoj
Oral presentation
Access to their own drugs': Navigating the drawbacks and benefits of injectable hydromorphone and diacetylmorphine treatment in Vancouver, BC
10:50
to
12:20
Knowledge market 3 (K3)
Samara Mayer
Oral presentation
Anti-doping knowledge and educational needs of Finnish pharmacists
10:50
to
12:20
Central square 2 (C2)
Jukka Koskelo
Oral presentation
The implementation of ultra-portable devices for analysis of illicit drug in drug checking service of the Canton of Vaud (Switzerland, CH)
10:50
to
12:20
Central square 2 (C2)
Emilia Gianola
Oral presentation
Characteristics of acute ecstasy-related toxicity in multiple Dutch medical settings, from 2009 through 2018
10:50
to
12:20
Central square 2 (C2)
Lonja Schurmann
Oral presentation
Metabolite profiling of synthetic cathinones: towards the identification of consumption biomarkers in forensic and clinical settings
10:50
to
12:20
Central square 2 (C2)
Alexandra Antunes
Oral presentation
Agreement between self-reported illicit drug use and biological samples: a systematic review and meta-analysis
10:50
to
12:20
Central square 2 (C2)
Chrianna Bharat
13:20
Oral presentation
2. Substance use disorders in refugee and migrant groups in Sweden: A nationwide cohort study of 1.2 million people
13:20
to
14:50
Insights zone 4 (I4)
Samantha Harris
Oral presentation
5. Services for vulnerable Migrants who use Drugs in the EU (SEMID-EU)
13:20
to
14:50
Insights zone 4 (I4)
Machteld Busz
Discussion
Ways forward: synthetizing priorities in prevalence studies and intervention needs in the EU
13:20
to
14:50
Insights zone 4 (I4)
Charlotte De Kock,
Klaudia Palczak
Oral presentation
3. Smartphone-based addiction prevention for young refugees: results of a feasibility study
13:20
to
14:50
Insights zone 4 (I4)
Lina-Sophia Falkenberg
Oral presentation
4. The Impact of the Russian Invasion of Ukraine on Needle and Syringe Distribution by Harm Reduction Organizations
13:20
to
14:50
Insights zone 4 (I4)
Benjamin Nikitin
Oral presentation
1. Equitable substance use treatment for migrants, refugees and ethnic minorities: An emerging research domain
13:20
to
14:50
Insights zone 4 (I4)
Inês Hasselberg
Oral presentation
A cluster randomised controlled trial of an eHealth intervention to prevent multiple lifestyle risk behaviours among Australian adolescents: Results from the Health4Life Study
13:20
to
14:50
Central square 3 (C3)
Katrina Champion
Oral presentation
Digital technologies to prevent drug overdoses. A UK perspective
13:20
to
14:50
Central square 3 (C3)
Alberto Oteo
Oral presentation
Feasibility and efficacy of the S-Check App to change help seeking behaviour of people who use methamphetamine
13:20
to
14:50
Central square 3 (C3)
Krista Siefried
Oral presentation
2. Design and Testing of an Aftercare Mobile App for Substance Use Among Young Adults: An Interdisicplinary Approach in Denmark
13:20
to
14:50
Insights zone 2 (I2)
Adriana del Palacio-Gonzalez
Oral presentation
1. Developing a functional taxonomy for Digital Health Interventions in Addiction Services
13:20
to
14:50
Central square 2 (C2)
Joseph Tay Wee Teck
Oral presentation
3. A guided digital intervention to reduce cannabis use: the ICan randomized controlled trial in the Netherland
13:20
to
14:50
Insights zone 2 (I2)
Marleen Olthof
Oral presentation
3. Immersive Virtual Reality in the Assessment and Treatment of Addictive Disorders: Current Status and Future Perspectives
13:20
to
14:50
Central square 2 (C2)
Simon Langener
Oral presentation
4. Boozebuster: A Mobile Intervention to Promote Low-Risk Drinking Habits in Young Adults –preliminary results
13:20
to
14:50
Insights zone 2 (I2)
Mieke Schulte
Oral presentation
4. Routine outcome monitoring and personalized clinical feedback for people in treatment for substance use disorders. A mixed-method adaptation study
13:20
to
14:50
Central square 2 (C2)
Øyvind Kyrre Grindheim
Discussion
Experiences with and opinions on (sub-)cultural adaptions and other forms of tailoring of digital addiction interventions to meet specific expectations of the target audience.
13:20
to
14:50
Insights zone 2 (I2)
Matthijs Blankers
Discussion
Are Digital Health Interventions for Addiction Services more likely to widen or narrow inequalities?
13:20
to
14:50
Central square 2 (C2)
Marica Ferri
Oral presentation
1. Guided smartphone-based treatment for patients in opioid maintenance treatment in Iran -transdiagnostic treatment for substance use and common mental disorders
13:20
to
14:50
Insights zone 2 (I2)
Michael Schaub
Oral presentation
2. Spanish version of CANreduce. Preliminary findings of a self-guided treatment program to reduce cannabis consumption
13:20
to
14:50
Central square 2 (C2)
Joan-Ignasi Mestre-Pintó
Oral presentation
Discontinuing chronic benzodiazepine use for insomnia with blended care: results of a pragmatic cluster-RCT
13:20
to
14:50
Central square 3 (C3)
Kristien Coteur
Oral presentation
2. Digital Health Interventions: Petiscos from clinical practice
13:20
to
14:50
Central square 2 (C2)
Roya Vaziri
Thursday, 24 November
10:50
Oral presentation
Non-drinking as deviant! First attempts to use the Relational Responding Task to alter drinking identity in an experimental study.
10:50
to
12:20
Insights zone 2 (I2)
Helle Larsen
Oral presentation
The Power of Social Networks: Trial Outcomes of a Two-Stage Social Network Intervention Aimed at Reducing Hazardous Drinking in the First Twelve Months at Residential College.
10:50
to
12:20
Insights zone 2 (I2)
Lily Davidson
Oral presentation
The association between social media use and substance use behaviour among adolescents: The ABCD-Study
10:50
to
12:20
Insights zone 2 (I2)
Hanan Bozhar
Oral presentation
Quem conta um conto acrescenta um ponto': Drugs as news in Portugal
10:50
to
12:20
Insights zone 2 (I2)
Pedro Barbosa
13:20
Oral presentation
Perceived barriers and facilitators to accessing effective clinical supervision and the implementation of a clinical supervision exchange model in the alcohol and other drug sector
13:20
to
14:50
Central square 1 (C1)
Courtney O'Donnell
Oral presentation
Using technology to digitally disrupt the delivery of outcome measures in Alcohol and Other Drug (AOD) services
13:20
to
14:50
Central square 1 (C1)
Leanne Hides
Oral presentation
Drinking with Coworkers – How to Make it a Safe and Including Event
13:20
to
14:50
Central square 1 (C1)
Stian Fjerdingen
Oral presentation
Accuracy, acceptability, and feasibility of transdermal alcohol sensors: Two systematic reviews
13:20
to
14:50
Central square 1 (C1)
Eileen Brobbin
15:00
Oral presentation
The role of place-making dynamics in recovery from co-occurring disorders: An in-depth ethnographic study
15:00
to
16:30
Knowledge market 2 (K2)
Clara De Ruysscher
Oral presentation
Online peer support for concurring mental health and addiction problems during the Covid19 pandemic: feeling of group inclusion and perceived effectiveness.
15:00
to
16:30
Knowledge market 2 (K2)
Raffaella Milani
Oral presentation
Changes in mental health among drug users during Covid-19. Evidence from a repeated cross-sectional survey in Belgium
15:00
to
16:30
Knowledge market 2 (K2)
Elena Damian
16:50
Short communication
The project „SubFAN': Transforming Social Work with Drug Consuming Football Fans into Digital Health Prevention
16:50
to
18:20
Networking zone 4 (N4)
Laura Arasteh-Roodsary
Short communication
Is digitization and gamification of prevention programs the way forward?
16:50
to
18:20
Networking zone 4 (N4)
Ana Ferreira
Short communication
Safety and health at the workplace and psychoactive substances use. Intervention model - 'Preventing and Intervening in workplace' and its application in Municipalities, Municipal Services and other public organizations.
16:50
to
18:20
Networking zone 4 (N4)
Carlos Ramos Cleto
Short communication
An Alcohol or other Drugs (AOD) policy at the workplace in the Netherlands. Barriers and solutions
16:50
to
18:20
Networking zone 4 (N4)
Maddy Blokland
Short communication
The environmental prevention project 'Responsible Sale of Alcohol and Tobacco - Support for sellers in the municipality of Sintra'
16:50
to
18:20
Networking zone 4 (N4)
Isabel Prata
Short communication
Does the total consumption model apply to gambling? A review of theory and evidence
16:50
to
18:20
Networking zone 4 (N4)
Viktorija Kesaite
Short communication
Public stigma and support for others help seeking for alcohol use disorders
16:50
to
18:20
Networking zone 4 (N4)
Sara Wallhed Finn
e-poster
High smoking and low cessation rates among patients in treatment for opioid and other substance use disorders
16:50
to
18:20
Networking zone 1 (N1)
Endre D. Bjørnestad
e-poster
Hepatitis C seroprevalence and associated factors among people who inject drugs (PWID) in Estonia
16:50
to
18:20
Networking zone 1 (N1)
Sigrid Vorobjov
e-poster
An ecological analysis of the spatial relationship between a network of supervised consumption services and overdose mortality incidence in Toronto, Canada.
16:50
to
18:20
Networking zone 1 (N1)
Indhu Rammohan
e-poster
Take-Home Naloxone and risk management among people who survived an opioid overdose; a qualitative analysis informed by drug, set and setting
16:50
to
18:20
Networking zone 1 (N1)
Elin Holmén
e-poster
Mortality and causes of death among persons with alcohol use disorder only versus persons with opioid dependence: results from a 19-year prospective cohort study.
16:50
to
18:20
Networking zone 1 (N1)
Ivar Skeie
e-poster
Identifying and tracking cases of suspected unintentional drug overdose deaths in near real-time using the Suspected Potential Overdose Tracker (SPOT)
16:50
to
18:20
Networking zone 1 (N1)
Karli Hochstatter
e-poster
Wearable technologies that may prevent, detect or respond to opioid overdose: a scoping review.
16:50
to
18:20
Networking zone 1 (N1)
Basak Tas
e-poster
Harm reduction behaviors are associated with carrying naloxone among patients on methadone treatment.
16:50
to
18:20
Networking zone 1 (N1)
Zofia Kozak
e-poster
Knowledge and attitude of community stakeholders towards harm reduction activities including Methadone treatment, needle and syringe exchange programs for drug users and injectors in Gaza Strip-Palestine (2019)
16:50
to
18:20
Networking zone 1 (N1)
Mohammed fathi Alafifi
Friday, 25 November
10:50
Oral presentation
European Web Survey on Drugs
10:50
to
12:20
Central square 4 (C4)
João Matias,
José Pedro Teixeira
Oral presentation
European Web Survey on Drugs - Luxembourg
10:50
to
12:20
Central square 4 (C4)
Rita Cardoso Seixas
Oral presentation
European Web Survey on Drugs - Ireland
10:50
to
12:20
Central square 4 (C4)
Nicki Killeen
Oral presentation
The experience of running web surveys in Belgium
10:50
to
12:20
Central square 4 (C4)
Elena Damian
Oral presentation
Web surveys on drugs - how can these be important for those who use drugs
10:50
to
12:20
Central square 4 (C4)
Lígia Parodi
13:20
Oral presentation
1. A novel way of enhancing adherence to acamprosate for alcohol dependence: The Alcohol Dependence and Adherence to Medicine (ADAM) trial
13:20
to
14:50
Networking zone 3 (N3)
Thomas Phillips
Oral presentation
2. Effectiveness and cost-effectiveness of face-to-face and electronic brief interventions versus screening alone to reduce alcohol consumption among high-risk adolescents presenting to Emergency Departments: three-arm pragmatic randomised trial
13:20
to
14:50
Networking zone 3 (N3)
Paolo Deluca
Oral presentation
3. Alcohol Assertive Outreach Treatment randomised controlled trial: a mixed methods economic evaluation
13:20
to
14:50
Networking zone 3 (N3)
Amy Wolstenholme
Discussion
Lessons for future clinical research trials and clinical practice
13:20
to
14:50
Networking zone 3 (N3)
Karl Mann